Research Analysts Issue Forecasts for NeuroDerm Ltd.’s FY2020 Earnings (NDRM)
NeuroDerm Ltd. (NASDAQ:NDRM) – Investment analysts at Oppenheimer Holdings issued their FY2020 earnings per share (EPS) estimates for shares of NeuroDerm in a research report issued to clients and investors on Thursday. Oppenheimer Holdings analyst J. Olson expects that the firm will earn $0.90 per share for the year.
NeuroDerm (NASDAQ:NDRM) last released its earnings results on Thursday, August 25th. The company reported ($0.32) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.32).
Several other brokerages have also recently weighed in on NDRM. Zacks Investment Research cut shares of NeuroDerm from a “hold” rating to a “sell” rating in a research note on Tuesday, August 30th. Jefferies Group raised their target price on shares of NeuroDerm from $28.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, September 6th.
NeuroDerm (NASDAQ:NDRM) opened at 18.40 on Monday. The firm’s market capitalization is $399.35 million. NeuroDerm has a 1-year low of $11.76 and a 1-year high of $20.52. The company’s 50-day moving average is $18.04 and its 200 day moving average is $17.43.
Several institutional investors have recently added to or reduced their stakes in NDRM. Scopia Capital Management LP boosted its position in NeuroDerm by 23.1% in the first quarter. Scopia Capital Management LP now owns 3,383,359 shares of the company’s stock valued at $47,773,000 after buying an additional 634,321 shares in the last quarter. Menora Mivtachim Holdings LTD. boosted its position in NeuroDerm by 209.7% in the second quarter. Menora Mivtachim Holdings LTD. now owns 590,724 shares of the company’s stock worth $9,599,000 after buying an additional 400,000 shares during the period. Adage Capital Partners GP L.L.C. bought a new position in NeuroDerm during the third quarter worth approximately $5,122,000. Sectoral Asset Management Inc. bought a new position in NeuroDerm during the second quarter worth approximately $1,706,000. Finally, Sectoral Asset Management Inc boosted its position in NeuroDerm by 54.3% in the third quarter. Sectoral Asset Management Inc now owns 161,971 shares of the company’s stock worth $2,995,000 after buying an additional 57,000 shares during the period. 42.93% of the stock is owned by institutional investors and hedge funds.
NeuroDerm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa/carbidopa (LD/CD) or apomorphine concentrations and dosages.
Receive News & Stock Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related stocks with our FREE daily email newsletter.